You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Moodys
Medtronic
Baxter
McKinsey

Last Updated: July 10, 2020

DrugPatentWatch Database Preview

Patent: 9,931,380

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,931,380
Title:Medicament for treating olfaction disorder
Abstract: The object of the present invention is to provide an olfactory disturbance therapeutic agent that is effective in repairing or regenerating olfactory epithelium that suffered damages such as scratches and can be administered for a long time. The object of the present invention is achieved by an olfactory disturbance therapeutic agent including at least one active ingredient that is selected from among a group consisting of insulin, insulin analogs, and insulin secretagogues. Preferably, the olfactory disturbance therapeutic agent is used for people with olfactory disturbance who have, or are at risk of having, impaired insulin secretion or insulin resistance, or for people who could suffer an iatrogenic increase in blood sugar level or a disturbance in a balance of adrenocortical hormone stemming from a long-term use of steroid as olfactory disturbance treatment.
Inventor(s): Kuboki; Akihito (Tokyo, JP), Kikuta; Shu (Tokyo, JP)
Assignee:
Application Number:15/046,858
Patent Claims:see list of patent claims

Details for Patent 9,931,380

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Mylan Pharms Inc SEMGLEE insulin glargine INJECTABLE;INJECTION 210605 001 2020-06-11   Start Trial 2035-02-19 RX search
Sanofi-aventis Us ADMELOG insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196 003 2018-10-19   Start Trial 2035-02-19 RX search
Sanofi-aventis Us ADMELOG SOLOSTAR insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196 002 2018-10-19   Start Trial 2035-02-19 RX search
Sanofi-aventis Us ADMELOG insulin lispro SOLUTION;INTRAVENOUS, SUBCUTANEOUS 209196 001 2018-10-19   Start Trial 2035-02-19 RX search
Eli Lilly And Co BASAGLAR insulin glargine SOLUTION;SUBCUTANEOUS 205692 001 2016-06-17   Start Trial 2035-02-19 RX search
Novo TRESIBA insulin degludec SOLUTION;SUBCUTANEOUS 203314 003 2015-09-25   Start Trial 2035-02-19 RX search
Novo TRESIBA insulin degludec SOLUTION;SUBCUTANEOUS 203314 002 2015-09-25   Start Trial 2035-02-19 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
McKinsey
Express Scripts
Dow
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.